# A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

> **NCT05268666** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jubilant Therapeutics Inc.** · enrollment: 126 (estimated)

## Conditions studied

- Locally Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** JBI-802

## Key facts

- **NCT ID:** NCT05268666
- **Lead sponsor:** Jubilant Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-08
- **Primary completion:** 2024-12
- **Final completion:** 2025-08
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268666, "A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05268666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*